1-855-378-42281-855-378-4228
One of the outpatient treatment options for individuals in Drayton Plains who are struggling with opioid dependence and addiction is opioid maintenance therapy. Some facilities and doctors are authorized to dispense certain meds to opioid dependent individuals, many that are opioid-based themselves and are habit forming. With low enough doses however, the client doesn't experience being high but also doesn't experience acute cravings and is not experiencing opioid withdrawal. Methadone is the first medication tried for this reason, but there are a few more choices to pick from.
Methadone is an opiate and can be taken at an outpatient medical center certified to administer the drug, which is taken on a daily basis as a pill or liquid. The price of the med is around under $200 per month. Buprenorphine is also an opioid based med, and is a pill often taken one day on, one day off. But different from Methadone which can only be given in structured clinics, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is around $300 monthly for the generic of the med. There is also a type of buprenorphine that contains the ingredient naloxone, which is a med which reverses the effects of opiates. A person consuming this version of the drug, also known as Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and is priced about $450 per month. Naltrexone is another medication taken in opioid maintenance therapy, but unlike the other medications mentioned it's an opioid blocker and is not an opiate. There is an option to take this drug as a monthly shot, which is called Vivitrol. As an opioid blocker, the drug prevents a person from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 per month.
For All Drug and Alcohol Rehabilitation Programs In Drayton Plains, Click Here.
